The only strategic consideration I can think of is that it might be wise for anybody considering publishing research analysing this data to publish their protocol before the data is released. Otherwise they are open to the allegation that they decided on their protocol after they had seen the data. That applies also to non-academic analyses of the data, i.e. any analyses that the patient community might wish to undertake.
I agree, but the main task, as I see it is to re-analyse the data according to their own original published protocol.
They've now done this for us for 'improvement', showing 20% in treatment groups, not the 60% they had claimed.
For me, the most interesting omission on their part is the results for their original definition of 'recovery'. All we need to do is count how many patients in each group fulfilled that protocol defined outcome. The fact that they haven't published it so far suggests the results were dire.
Putting these two together should be sufficient to demolish the trial and declare it a null result. The fact that the 2 year follow up has already been published and shows no between group differences simply confirms this.
I think our main problem now is to find ways of publicising this, and getting NICE guidelines, Cochrane review, textbooks, medical training, ME/CFS clinics, doctors, the Medical research council, the Lancet, employers, government benefits agencies, insurance companies, the media including the Science Media Centre etc. to accept the null finding as definitive proof that GET and CBT don't work, and act accordingly.
And all PACE papers retracted and addenda added to any other research papers that have quoted it. And the MAGENTA trial stopped...
And as a bonus, to get the researchers involved to admit publicly and contritely that they have been spinning and pushing a false story about the causes and treatment of ME and CFS!
And pigs might fly!
This is, sadly, only the beginning of the next phase of a very long fight.
But I'm so grateful for those who have taken the fight this far, especially Alem Mathees.